Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
133 studies found for:    Open Studies | "Thyroid Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
Condition: Thyroid Neoplasms
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Other Multikinase inhibitors
2 Recruiting Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer
Condition: Thyroid Neoplasms
Interventions: Drug: I-131;   Drug: I-125
3 Recruiting Institut Paoli Calmettes Thyroid Cancer Database
Condition: Thyroid Neoplasms
Intervention: Other: Data collection
4 Recruiting Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Condition: Thyroid Neoplasms
Intervention: Drug: Lenvatinib
5 Recruiting Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer
Condition: Thyroid Neoplasms
Intervention:
6 Recruiting Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Condition: Thyroid Cancer
Intervention: Drug: Sorafenib
7 Recruiting Diagnosing Thyroid Cancer Using a Blood Test
Condition: Differentiated Thyroid Cancer
Intervention:
8 Recruiting Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia
Conditions: Thyroid Neoplasms;   Thyroid Cancer
Intervention: Procedure: Histological investigation of the SN
9 Recruiting Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study
Condition: Thyroid Cancer
Intervention:
10 Recruiting A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer
Conditions: Anaplastic Thyroid Cancer;   Thyroid Cancer
Intervention: Drug: MLN0128
11 Recruiting IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Condition: Thyroid Cancer
Intervention: Radiation: I131 1.1 GBq
12 Recruiting A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Drug: Regorafenib
13 Recruiting Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
Condition: Differentiated Thyroid Cancer
Intervention:
14 Recruiting Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
Condition: Anaplastic Thyroid Cancer
Intervention: Drug: Lenvatinib
15 Recruiting The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Dietary Supplement: thymus honey mouthwash
16 Recruiting Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Condition: Thyroid Cancer
Interventions: Drug: Vemurafenib (All Groups);   Drug: Vemurafenib (Post Surgery) - Group A + C;   Other: Post Surgery - Group B
17 Recruiting A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Interventions: Drug: Cabozantinib (XL184) 140 mg;   Drug: Cabozantinib (XL184) 60 mg;   Drug: Placebo tablet;   Drug: Placebo capsule
18 Recruiting Hereditary Risk Factors for Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Genetic: •Referral to Genetic Counselor, if indicated
19 Recruiting An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)
Conditions: Thyroid Neoplasms;   Head and Neck Neoplasms
Interventions: Drug: C-PERT;   Drug: G-PERT
20 Recruiting A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Conditions: Differentiated Thyroid Cancer (DTC);   Poorly Differentiated Thyroid Cancer
Intervention: Drug: Cabozantinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.